Centre National De La Recherche Scientifique

Institut Curie

Institut National De La Sante Et De La Recherche Medicale

Université Pierre Et Marie Curie (Paris Vi)

Commissariat a L'energie Atomique Et Aux Energies Alternatives

Institute Curie

Université Pierre Et Marie Curie (Paris 6)

Université Pierre Et Marie Curie - Upmc

Insem-transfert

Institut Curie and Centre National De La Recherche Scientifique

Commissariat À L'énergie Atomique Et Aux Énergies Alternatives

Centre National De La Recherche Scientifique-cnrs

Ludger Johannes

Bruno Goud

David Grierson

Daniel Gillet

Sylvie Robine

Julien Barbier

Eric Tartour

Jean-Claude Florent

Jacky Roger

Wolf Herve Fridman

Siau-Kun Bai

Bahne Stechmann

Jean-Christophe Cintrat

Allan M Green

Philipe Maillard

Romain Noel

The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein:

Universal carrier for targeting molecules to GB3 receptor expressing cells

The present invention concerns a new family of 2,3-dihydroquinazolin-4(1H)-one compounds of general formula (I), and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as ricin or Shiga toxin, for example, using retrograde transport to intoxicate cells.

Compounds having a protective activity against toxins with intracellular activity

The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.

Inhibitors of the shiga toxins trafficking through the retrograde pathway

Universal carrier for targeting molecules to Gb3 receptor expressing cells

Inhibitors of the Shiga toxins trafficking through the retrograde pathway

The invention pertains to methods for using chimeric polypeptides of the formula:B-Xwherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.

Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest

The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gbreceptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein

[object Object]

Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors

The invention relates to new compounds for cancer therapy or diagnosis and to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein-STxB is the Shiga Toxin B subunit or a functional equivalent thereof, -Z(n) wherein n is 0 or 1, Z is an amino-acid residue devoid of sulfydryl groups, or is a polypeptide, -T is a molecule linked by a covalent bound to the S part of Cys, selected from: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, - Y(m) wherein m is 0 or 1, Y is a linker between T and Cys, which is either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into cells.

The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.

The invention pertains to methods for using chimeric polypeptides of the formula:B&#x2014;Xwherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B&#x2014;X are also included.

Growing community of inventors

Courbevoie, France

Ludger Johannes